Cancer is a disease of genes, not bad luck alone
In the first guide of this rung you saw cancer from the outside: a cell that divides when it should rest, ignores its neighbours, and spreads. This guide goes one level down to ask *why* that cell behaves so badly — and the answer is almost always written in its DNA. A cancer cell is running corrupted instructions. The very genes that normally tell a cell when to grow, when to stop, and when to die have been altered, and the cell now obeys the broken version. This is what people mean when they say cancer is fundamentally a genetic disease: not usually inherited, but driven by changes to the genome of a single cell and its descendants.
Recall the engine-and-brakes picture from the cell-cycle control guide: the cell cycle is driven forward by accelerators and held back by brakes. Cancer happens when a few of those controls fail in two complementary ways — an accelerator gets jammed in the 'on' position, and a brake gets cut. The genes behind those two failures have names. The jammed accelerators are oncogenes. The cut brakes are tumor suppressors. Nearly everything in cancer genetics is some variation on these two themes, so it is worth getting the distinction crystal clear.
Oncogenes: an accelerator jammed on
Here is the first surprise, and it overturns how most people first imagine cancer genes. An oncogene does not arrive from outside, foreign and alien. It starts life as a perfectly normal, useful gene called a proto-oncogene. Proto-oncogenes are the genes that *should* drive cell growth — at the right time, in the right amount. They build the growth-factor receptors on the cell surface, the relay proteins like protein kinases that carry a 'divide now' message inward, and the switches that turn the cell cycle on. In a healthy cell these are the gas pedal, and pressing the gas pedal is a normal, necessary thing to do.
An oncogene is what a proto-oncogene becomes when a mutation jams it permanently into the 'on' state. The gene now screams 'divide!' all the time, whether or not any real growth signal has arrived. This can happen in several ways: a single letter change can lock the protein into its active shape (the famous RAS oncogenes do exactly this); a gene can be copied too many times so the cell makes far too much of it (amplification); or it can land next to the wrong control switch and be transcribed wildly (as in some leukaemias). The route differs, but the result is the same — a relay that should fire only on command is now stuck firing.
Tumor suppressors: a brake that fails
The other half of the story is the brakes. A tumor suppressor is a gene whose normal job is to *restrain* division — to slow the cycle, fix damage before it spreads, or, in the worst case, order a dangerous cell to die. Where an oncogene goes wrong by doing too much, a tumor suppressor goes wrong by being switched off entirely. This is a 'loss of function': the protective protein is gone, and nothing is left to say 'stop'. Cancer needs both kinds of failure — the gas stuck down *and* the brakes gone — which is why these two gene families are the twin pillars of cancer genetics.
Two tumor suppressors are worth knowing by name. The first is Rb (the retinoblastoma protein), the guard at the G1 'go/no-go' decision. In a resting cell Rb physically clamps down the proteins that would launch DNA copying, holding the cycle still — it is the brake pedal pressed to the floor. Only a genuine, sustained growth signal causes the cyclin–CDK engine to phosphorylate Rb and release its grip, letting the cell commit. Lose Rb and that pedal is gone: the cell tips into division without ever being asked to. The second is p53, which you met in the cell-cycle guide as the guardian of the genome. When DNA is damaged, p53 piles up, pauses the cycle so repair crews can work, and — if the damage is beyond fixing — triggers programmed cell death rather than let a corrupted cell divide.
The multi-hit model: why one mutation is not enough
If a single jammed accelerator could make a cancer, we would all develop tumors as children, because mutations happen constantly. They do not, and the reason is that the cell is protected by layered, overlapping safeguards on purpose. Turning a normal cell fully cancerous usually requires *several* independent changes that accumulate over years — an oncogene switched on, one tumor suppressor knocked out, then another, then the controls on cell death or telomere length defeated. This is the multi-hit model of cancer: not one catastrophic event, but a slow stacking of damage. It is why most cancers are diseases of later life, and why the hallmarks of cancer are acquired one capability at a time.
There is a vicious twist that makes the stacking faster. Some of the genes that get knocked out are the very ones that guard the genome — the p53 alarm and the DNA-repair machinery. Once those fail, the cell can no longer pause to fix damage or kill itself when it should. Mutations that would once have been caught now pile up unchecked, including mutations in *more* cancer genes. The result is a runaway: each broken safeguard makes the next hit easier to acquire. Biologists call this the cell becoming genomically *unstable*, and it is the engine that turns a slow process into a relentless one.
normal cell
| hit 1: proto-oncogene --> ONCOGENE (accelerator jammed on)
v
slightly faster-growing clone
| hit 2: lose 1st copy of a tumor suppressor (still 1 brake)
v
small benign growth
| hit 3: lose 2nd copy --> brake GONE
| hit 4: p53 / repair disabled --> instability
v
invasive cancer (each hit selects the fastest-growing cells)Inherited vs sporadic: the two-hit head start
The two-copy rule for tumor suppressors explains one of the most important distinctions in cancer: why a small fraction of cancers run in families. In the common, sporadic kind, a cell starts with two good copies of every tumor suppressor, and both copies must be damaged *by chance* within that one cell's lifetime. Knocking out both copies of the same gene in the same cell is rare, so it usually takes decades — which is why most cancer is sporadic and appears later in life. The dice simply have to land badly, twice, in one place.
Now consider someone born with an inherited faulty copy of a tumor suppressor — passed down in the egg or sperm, so it sits in *every* cell of their body from the start. They are not born with cancer. But every cell already has one of its two brake copies broken; only one more chance hit is needed to lose the second. That single head start changes the odds enormously. It is the classic 'two-hit hypothesis', first worked out for the childhood eye tumor retinoblastoma: children who inherit one broken Rb copy develop tumors young and often in both eyes, while children with two good copies need both hits to happen by chance and get the rare, one-sided, later form.
Two honest cautions. First, an inherited cancer gene raises *risk*, not certainty — you inherit a head start, not a diagnosis, and the other hits still have to happen. Second, even hereditary cancer is not contagious and you cannot 'catch' it; what is passed down is a single faulty gene copy, after which the disease still develops by the same multi-hit logic playing out in one of your own cells.
The genetic logic, and how it fights back
Step back and the whole logic clicks into place. A cancer is a small population of cells that has, over time, collected a winning hand of mutations: oncogenes pressing the gas, tumor suppressors releasing the brakes, and the genome's guardians disabled so the hand can grow. Each new mutation that helps the cell divide faster gives it an edge, so the fastest-growing cells outcompete their neighbours — cancer is evolution by natural selection, sped up and turned inward against the body. That single idea ties together everything you have learned about the cell cycle, signaling, and DNA repair on this ladder.
Crucially, this same genetic logic is how medicine fights back. Because an oncogene often jams one specific protein into the 'on' state, a drug shaped to block *that one* protein can switch the stuck accelerator off — targeted therapies against mutant kinases work precisely this way, hitting the cancer cell where the healthy cell does not depend on the mutation. Reading a tumor's mutations now guides which drug to try. The harder problem is the lost brakes: you cannot easily hand a cell back a tumor suppressor it has deleted, which is why restoring p53 or Rb function remains one of the great unsolved challenges. Understanding the genes did not just explain cancer — it rebuilt how we treat it.